Moxetumomab 莫塞妥莫单抗

Indications

Hairy cell leukemia

Efficacy

Moxetumomab was approved by the FDA on September 13, 2018 for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL). These patients must have received at least two systemic therapies, including purine nucleoside analog (PNA) therapy.

Moxetumomab is a CD22 antibody-drug conjugate (ADC) that recognizes human CD22. CD22 is a transmembrane protein expressed only in B lymphocytes. It has a higher density of receptors on the surface of HCL cells. After binding to CD22, this molecule enters the cell, is processed and releases toxin proteins, which inhibit protein translation and lead to cell apoptosis.

Adverse reactions

The most common (≥20%) adverse reactions are infusion-related reactions, edema, nausea, fatigue, headache, fever, constipation, anemia and diarrhea. The most common (≥50%) laboratory abnormalities were increased creatinine, increased ALT, hypoalbuminemia, increased AST, hypocalcemia, and hypophosphatemia.